United Therapeutics Corporation has agreed to acquire SteadyMed for $216m.

United Therapeutics will purchase SteadyMed for $4.46 a share in cash and additional $2.63 a share upon commercialisation of Trevyent. The transaction also includes a payment of $75m towards contingent consideration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based in the US, United Therapeutics is a biotechnology company, while SteadyMed is a pharmaceutical company based in Israel.

The acquisition will strengthen United Therapeutics’ product pipeline.

United Therapeutics has appointed Gibson, Dunn & Crutcher and Herzog, Fox & Neeman as legal advisers, while SteadyMed has appointed Cooley and Yigal Arnon & Co. as legal advisers for the transaction.

Wedbush PacGrow Life Sciences has been appointed as financial adviser to SteadyMed.

Par Formulations, a subsidiary of Endo International, has agreed to acquire Wintac.

Par Formulations will acquire Wintac along with property located in Bangalore, India, and the manufacturing plants for $30m.

Wintac will operate as a subsidiary of Par Pharmaceutical, upon completion of the acquisition in the second half of this year.

Based in India, Par Formulations is a contract research and manufacturing services provider.

“Par Formulations, a subsidiary of Endo International, has agreed to acquire Wintac.”

Endo Ventures and Par Pharmaceutical have signed an agreement to acquire Somerset Therapeutics from Mendham Holdings and other sellers.

Par Pharma will acquire the entire interests of Somerset, while Endo Ventures will acquire Somerset’s assets for $160m, as part of the transaction.

Somerset Therapeutics will become part of Par Pharma, upon completion of the acquisition in the second half of this year.

Endo Ventures and Par Pharmaceutical are pharmaceutical companies based in India and subsidiaries of Endo International.

Endo has appointed K&L Gates and Shardul Amarchand Mangaldas & Co as legal advisers for the transaction.

US-based biopharmaceutical company Janssen Biotech has agreed to acquire BeneVir Biopharm from HC2 Holdings, which holds 76% of the former’s equity.

HC2 Holdings will receive an upfront payment of $140m and additional contingent payments of up to $900m from Janssen, as part of the transaction. The total consideration is expected to cross approximately $1bn, upon completion of all milestone payments.

The acquisition will enhance BeneVir’s position in the oncolytic viral immunotherapy field.